• Wilfredo F Garcia-Beltran, Evan C Lam, Kerri St Denis, Adam D Nitido, Zeidy H Garcia, Blake M Hauser, Jared Feldman, Maia N Pavlovic, David J Gregory, Mark C Poznansky, Alex Sigal, Aaron G Schmidt, A John Iafrate, Vivek Naranbhai, and Alejandro B Balazs.
• Department of Pathology, Massachusetts General Hospital, Boston, MA 02114, USA; Department of Pathology, Brigham and Women's Hospital, Boston, MA 02115, USA.
• Cell. 2021 Apr 29; 184 (9): 2372-2383.e9.

AbstractVaccination elicits immune responses capable of potently neutralizing SARS-CoV-2. However, ongoing surveillance has revealed the emergence of variants harboring mutations in spike, the main target of neutralizing antibodies. To understand the impact of these variants, we evaluated the neutralization potency of 99 individuals that received one or two doses of either BNT162b2 or mRNA-1273 vaccines against pseudoviruses representing 10 globally circulating strains of SARS-CoV-2. Five of the 10 pseudoviruses, harboring receptor-binding domain mutations, including K417N/T, E484K, and N501Y, were highly resistant to neutralization. Cross-neutralization of B.1.351 variants was comparable to SARS-CoV and bat-derived WIV1-CoV, suggesting that a relatively small number of mutations can mediate potent escape from vaccine responses. While the clinical impact of neutralization resistance remains uncertain, these results highlight the potential for variants to escape from neutralizing humoral immunity and emphasize the need to develop broadly protective interventions against the evolving pandemic.Copyright © 2021 The Author(s). Published by Elsevier Inc. All rights reserved.

26 keywords...

hide…